Article info

Download PDFPDF

Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12–15 years
Free

Authors

  1. Correspondence to Dr Marion Roderick, Paediatric Infectious disease & Immunology, Bristol Royal Hospital for Children, Bristol BS2 8BJ, UK; rodericks1000{at}hotmail.com
View Full Text

Citation

King H, Deshpande S, Woodbridge T, et al
Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12–15 years

Publication history

  • Accepted August 12, 2021
  • First published August 26, 2021.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.